FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
Company Details
- Employees
- 14
- Founded
- -
- Address
- 村岡東二丁目26番地の1, 藤沢市,神奈川県 251-0012,japan
- Phone
- +81-466-32-1169
- in****@****ecs.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- fimecs.com
- Keywords
- Drug Discovery, Undruggable, Pseudokinase, Mid-size Molecule, Bi-functional Compound, Oncology, Immuno-oncology, Protein Degrader, Targeted Protein Degradation.
- HQ
- 藤沢市, 神奈川県
Fimecs, Inc. Questions
Fimecs, Inc.'s helpline number is +81-466-32-1169
Fimecs, Inc.'s website is fimecs.com
Fimecs, Inc.'s LinkedIn profile is https://jp.linkedin.com/company/fimecs
Fimecs, Inc. has
14 employees.
View email and phone details for 14
employees at Fimecs, Inc..
Fimecs, Inc.'s industry is
Pharmaceutical Manufacturing
Fimecs, Inc.'s top competitors are
Prism Biolab Co., Ltd.,
ラクオリア創薬（株）,
Azuriris, Inc.,
Chugai Pharmaceutical Co., Ltd.,
Gexval Inc.,
Cardurion Pharmaceuticals,
Shonan Health Innovation Park,
Axcelead, Inc.,
Bitbiome, Inc.,
Axcelead Drug Discovery Partners, Inc..
Fimecs, Inc.'s support email address is info@fimecs.com
Fimecs, Inc.'s categories are Pharmaceutical Manufacturing
Fimecs, Inc.'s founding year is 2018
